Ovarian cancer (OC) is the deadliest gynaecological malignancy. Identifying new prognostic biomarkers is an important research field. Haemostatic components together with leukocytes can drive cancer progression while increasing the susceptibility to venous thromboembolism (VTE) through immunothrombosis. Unravelling the underlying complex interactions offers the prospect of uncovering relevant OC prognostic biomarkers, predictors of cancer-associated thrombosis (CAT), and even potential targets for cancer therapy. Thus, this study evaluated the expression ofF3,F5,F8,F13A1,TFPI1, andTHBDin peripheral blood cells (PBCs) of 52 OC patients. Those with VTE after tumour diagnosis had a worse overall survival (OS) compared to their counterparts (mean OS of 13.8 ± 4.1 months and 47.9 ± 5.7 months, respectively; log-rank test,p= 0.001). Low pre-chemotherapyF3andF8expression levels were associated with a higher susceptibility for OC-related VTE after tumour diagnosis (χ2,p< 0.05). Regardless of thrombogenesis, patients with low baselineF8expression had a shorter progression-free survival (PFS) than their counterparts (adjusted hazard ratio (aHR) = 2.54;p= 0.021). Among those who were not under platelet anti-aggregation therapy, lowF8levels were also associated with a shorter OS (aHR = 6.16;p= 0.006). Moving forward, efforts should focus on external validation in larger cohorts.
卵巢癌是致死率最高的妇科恶性肿瘤。寻找新的预后生物标志物是该领域的重要研究方向。止血成分与白细胞共同作用可通过免疫血栓形成机制促进癌症进展，同时增加静脉血栓栓塞的易感性。揭示其背后复杂的相互作用机制，有望发现相关的卵巢癌预后生物标志物、癌症相关血栓形成的预测因子，甚至潜在的治疗靶点。本研究检测了52例卵巢癌患者外周血细胞中F3、F5、F8、F13A1、TFPI1和THBD的表达水平。肿瘤诊断后发生静脉血栓栓塞的患者总生存期显著差于未发生者（平均总生存期分别为13.8±4.1个月和47.9±5.7个月；时序检验p=0.001）。化疗前F3和F8低表达与肿瘤诊断后发生卵巢癌相关静脉血栓栓塞的高风险相关（χ2检验p<0.05）。无论是否发生血栓，基线F8低表达患者的无进展生存期均较短（校正风险比=2.54；p=0.021）。在未接受血小板抗聚集治疗的患者中，F8低表达也与较短的总生存期相关（校正风险比=6.16；p=0.006）。未来研究需在更大规模队列中进行外部验证。
肿瘤(癌症)患者之家